Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 3/20 | 0.69 |
| ▸ | METAP1 | P53582 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | SLC16A3 | O15427 | 3/20 | 0.48 |
| ▸ | FABP4 | P15090 | 1/20 | 0.48 |
| ▸ | ACLY | P53396 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | NEK2 | P51955 | 1/20 | 0.46 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3985999 | 0.88 | METAP2 (0.74) | METAP2METAP1SLC16A3ACLYTSHR | |
| SCHEMBL3982813 | 0.86 | METAP2 (0.52) | METAP2METAP1KDM4ESLC16A3FABP4 | |
| SCHEMBL4277652 | 0.84 | METAP2 (0.69) | METAP2METAP1TSHRMCL1MEN1 | |
| SCHEMBL3979302 | 0.84 | METAP2 (0.69) | METAP2METAP1SLC16A3TSHRMCL1 | |
| SCHEMBL3986500 | 0.82 | METAP2 (1.00) | METAP2METAP1CHEK1CDK8NEK2 | |
| SCHEMBL3982656 | 0.82 | METAP2 (1.00) | METAP2METAP1CHEK1CDK8NEK2 | |
| SCHEMBL3987476 | 0.81 | METAP2 (0.76) | METAP2METAP1FABP4TSHRCHEK1 | |
| SCHEMBL3982809 | 0.81 | METAP2 (0.67) | METAP2METAP1FABP4ACLYCHEK1 | |
| SCHEMBL3982685 | 0.81 | METAP2 (0.67) | METAP2METAP1SLC16A3FABP4CHEK1 | |
| SCHEMBL3982436 | 0.81 | METAP2 (0.61) | METAP2METAP1KDM4EFABP4ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040068012-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-04-08 | — | — | US | claimed |
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
| US-20040068012-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | METAP2 1/4885METAP1 2/4885KDM4E 2363/4885 |
| US-20040068012-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | METAP2 1/4885METAP1 2/4885KDM4E 2363/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | METAP2 1/4885METAP1 2/4885KDM4E 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.